- Tagrisso (osimertinib) plus chemotherapy approved in EU for 1st-line treatment of advanced EGFR-mutated lung cancer
July 05 2024 06:08:22 UTC– AstraZeneca’s drug Tagrisso (osimertinib) has been approved in the European Union for use as a first-line treatment for adults with advanced non-small cell lung cancer (NSCLC) that has specific genetic mutations.
These mutations occur in the epidermal growth factor receptor (EGFR) gene, specifically deletions in exon 19 or mutations in exon 21 (L858R).
The approval is for using Tagrisso in combination with two other chemotherapy drugs, pemetrexed and platinum-based chemotherapy.
This combination therapy is intended for patients whose cancer has spread and who have not received previous treatment.
By targeting the EGFR mutations, Tagrisso aims to more effectively treat this type of lung cancer, potentially improving outcomes for patients with these specific genetic profiles.